In an effort to better understand the impact of HPV status on the response to anti-PD1 immunotherapy, a meta-analysis has recently been published: Galvis MM et al. [98], assessing data collected from 11 clinical trials including 1860 R/M HNSCC patients treated with immunotherapy, reported that HPV-positive tumors were more responsive to immunotherapy than HPV-negative tumors for all outcome parameters they analyzed. The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.